MX2009003126A - Agente para prevenir/tratar el cancer. - Google Patents
Agente para prevenir/tratar el cancer.Info
- Publication number
- MX2009003126A MX2009003126A MX2009003126A MX2009003126A MX2009003126A MX 2009003126 A MX2009003126 A MX 2009003126A MX 2009003126 A MX2009003126 A MX 2009003126A MX 2009003126 A MX2009003126 A MX 2009003126A MX 2009003126 A MX2009003126 A MX 2009003126A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- protein
- prophylactic
- therapeutic agent
- cancer cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se da a conocer un anticuerpo monoclonal humano dirigido contra una proteína que tiene una secuencia de aminoácidos que es la misma o sustancialmente la misma que la secuencia de aminoácidos ilustrada en la SEQ ID NO: 1 ó 3, un péptido parcial de la proteína, o una sal de la proteína. El anticuerpo monoclonal humano es útil como un agente profiláctico o terapéutico para el cáncer, un promotor de la apoptosis de las células de cáncer, un inhibidor de la proliferación de las células de cáncer, un agente citotóxico para una célula de cáncer que utiliza un mecanismo de biodefensa por medio de una región Tc de un anticuerpo, o similares.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/320429 WO2007043635A1 (ja) | 2005-10-07 | 2006-10-06 | 癌の予防・治療剤 |
ARP070101453A AR060362A1 (es) | 2005-10-07 | 2007-04-04 | Agente para prevenir / tratar el cancer |
JP2007100876 | 2007-04-06 | ||
PCT/JP2007/069908 WO2008044754A1 (fr) | 2006-10-06 | 2007-10-04 | Agent prophylactique ou thérapeutique pour le cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003126A true MX2009003126A (es) | 2009-04-06 |
Family
ID=44083820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003126A MX2009003126A (es) | 2006-10-06 | 2007-10-04 | Agente para prevenir/tratar el cancer. |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100008928A1 (es) |
EP (1) | EP2067791A4 (es) |
JP (1) | JPWO2008044754A1 (es) |
KR (1) | KR20090078339A (es) |
CN (1) | CN101541834A (es) |
AR (1) | AR063153A1 (es) |
AU (1) | AU2007307536A1 (es) |
BR (1) | BRPI0717024A2 (es) |
CA (1) | CA2666249A1 (es) |
CL (1) | CL2007002879A1 (es) |
CO (1) | CO6190538A2 (es) |
EC (1) | ECSP099276A (es) |
IL (1) | IL197389A0 (es) |
MA (1) | MA30816B1 (es) |
MX (1) | MX2009003126A (es) |
NO (1) | NO20091783L (es) |
PE (1) | PE20081456A1 (es) |
RU (1) | RU2009117237A (es) |
TN (1) | TN2009000090A1 (es) |
TW (1) | TW200823235A (es) |
WO (1) | WO2008044754A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012092374A2 (en) | 2010-12-31 | 2012-07-05 | Short Jay M | Express humanization of antibodies |
BR112014002613B1 (pt) * | 2011-08-04 | 2022-08-23 | Toray Industries, Inc. | Anticorpo ou um fragmento do mesmo, composição farmacêutica, dna, uso de um anticorpo e uso de uma composição farmacêutica |
MX2014014951A (es) * | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. |
WO2014069681A1 (ko) * | 2012-10-29 | 2014-05-08 | 인제대학교 산학협력단 | 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
WO2014069682A1 (ko) * | 2012-10-29 | 2014-05-08 | 인제대학교 산학협력단 | 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
PL3295951T3 (pl) | 2015-02-19 | 2020-10-05 | Compugen Ltd. | Przeciwciała anty-pvrig i sposoby ich zastosowania |
EP3978929A1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
WO2018033798A1 (en) | 2016-08-17 | 2018-02-22 | Compugen Ltd. | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
EP3548071A4 (en) | 2016-11-30 | 2020-07-15 | OncoMed Pharmaceuticals, Inc. | METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES |
BR112019025035A2 (pt) | 2017-06-01 | 2020-06-30 | Compugen Ltd. | método para tratar câncer |
EP3823673A4 (en) | 2018-07-20 | 2022-05-11 | Surface Oncology, Inc. | ANTI-CD112R COMPOSITIONS AND METHODS |
KR20230133331A (ko) | 2021-01-15 | 2023-09-19 | 씨젠 인크. | 면역조절 항체-약물 컨쥬게이트 |
WO2022170002A1 (en) | 2021-02-03 | 2022-08-11 | Seagen Inc. | Immunostimulatory compounds and conjugates |
WO2023161943A1 (en) * | 2022-02-28 | 2023-08-31 | Nectin Therapeutics Ltd. | Humanized antibodies against nectin-2 and drug conjugates thereof |
WO2023215740A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
WO2024030577A1 (en) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Immunostimulatory anti-pd-l1-drug conjugates |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
WO1999063063A1 (en) | 1998-06-03 | 1999-12-09 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
US20030129685A1 (en) * | 1998-10-28 | 2003-07-10 | Jian Ni | 12 human secreted proteins |
DE19852800C1 (de) | 1998-11-16 | 2000-04-13 | Univ Albert Ludwigs Freiburg | Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist |
US20030022279A1 (en) * | 1999-06-14 | 2003-01-30 | Fraser Christopher C. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
WO2002000677A1 (en) | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU1305302A (en) | 2000-10-05 | 2002-04-15 | Immunex Corp | Nectin polypeptides, polynucleotides, methods of making and use thereof |
JP2004528043A (ja) | 2001-06-05 | 2004-09-16 | エクセリクシス・インコーポレイテッド | p53経路のモディファイヤーとしてのCHDsおよび使用方法 |
EP1392111A4 (en) | 2001-06-06 | 2004-07-28 | Regeneron Pharma | METHOD FOR TARGETING TRANSCRIBING ACTIVE LOCUSES |
WO2003020743A1 (en) | 2001-09-05 | 2003-03-13 | Regeneron Pharmaceuticals, Inc. | Methods of expressing transgenes |
EP1571968A4 (en) * | 2002-04-16 | 2007-10-17 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS |
AU2003295328A1 (en) | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1733743A4 (en) | 2004-04-09 | 2007-06-27 | Takeda Pharmaceutical | PREVENTIVE / REMEDY AGAINST CANCER |
-
2007
- 2007-10-04 AU AU2007307536A patent/AU2007307536A1/en not_active Abandoned
- 2007-10-04 US US12/444,382 patent/US20100008928A1/en not_active Abandoned
- 2007-10-04 PE PE2007001348A patent/PE20081456A1/es not_active Application Discontinuation
- 2007-10-04 WO PCT/JP2007/069908 patent/WO2008044754A1/ja active Application Filing
- 2007-10-04 JP JP2008538759A patent/JPWO2008044754A1/ja not_active Withdrawn
- 2007-10-04 CN CNA2007800371476A patent/CN101541834A/zh active Pending
- 2007-10-04 BR BRPI0717024-6A2A patent/BRPI0717024A2/pt not_active IP Right Cessation
- 2007-10-04 EP EP07829644A patent/EP2067791A4/en not_active Withdrawn
- 2007-10-04 CA CA002666249A patent/CA2666249A1/en not_active Abandoned
- 2007-10-04 MX MX2009003126A patent/MX2009003126A/es not_active Application Discontinuation
- 2007-10-04 RU RU2009117237/10A patent/RU2009117237A/ru not_active Application Discontinuation
- 2007-10-04 KR KR1020097009036A patent/KR20090078339A/ko not_active Application Discontinuation
- 2007-10-05 CL CL200702879A patent/CL2007002879A1/es unknown
- 2007-10-05 TW TW096137411A patent/TW200823235A/zh unknown
- 2007-10-09 AR ARP070104425A patent/AR063153A1/es unknown
-
2009
- 2009-03-03 IL IL197389A patent/IL197389A0/en unknown
- 2009-03-16 TN TN2009000090A patent/TN2009000090A1/fr unknown
- 2009-04-23 EC EC2009009276A patent/ECSP099276A/es unknown
- 2009-04-27 MA MA31823A patent/MA30816B1/fr unknown
- 2009-05-04 CO CO09044621A patent/CO6190538A2/es not_active Application Discontinuation
- 2009-05-05 NO NO20091783A patent/NO20091783L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA30816B1 (fr) | 2009-10-01 |
IL197389A0 (en) | 2011-08-01 |
EP2067791A1 (en) | 2009-06-10 |
CO6190538A2 (es) | 2010-08-19 |
KR20090078339A (ko) | 2009-07-17 |
RU2009117237A (ru) | 2010-11-20 |
TW200823235A (en) | 2008-06-01 |
AR063153A1 (es) | 2008-12-30 |
AU2007307536A2 (en) | 2009-04-30 |
NO20091783L (no) | 2009-07-01 |
BRPI0717024A2 (pt) | 2014-03-11 |
TN2009000090A1 (en) | 2010-08-19 |
EP2067791A4 (en) | 2009-11-25 |
CA2666249A1 (en) | 2008-04-17 |
AU2007307536A1 (en) | 2008-04-17 |
JPWO2008044754A1 (ja) | 2010-02-18 |
CN101541834A (zh) | 2009-09-23 |
WO2008044754A1 (fr) | 2008-04-17 |
US20100008928A1 (en) | 2010-01-14 |
PE20081456A1 (es) | 2008-11-27 |
CL2007002879A1 (es) | 2008-06-27 |
ECSP099276A (es) | 2009-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009003126A (es) | Agente para prevenir/tratar el cancer. | |
MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
PH12014501083A1 (en) | Anticancer fusion protein | |
NZ599204A (en) | High affinity human antibodies to human protease-activated receptor-2 | |
UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
NZ595825A (en) | Antibody containing igg2 having amino acid mutation introduced therein | |
IN2014KN01715A (es) | ||
MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
WO2006103666A3 (en) | Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
EA201291362A1 (ru) | Слитый белок против злокачественных новообразований | |
WO2006113681A3 (en) | Plant-derived elastin binding protein ligands and methods of using the same | |
CA2648109A1 (en) | Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine | |
NZ594480A (en) | Methods and compositions for diagnosis and treatment of cancer | |
MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
NZ603196A (en) | Methods of use of soluble cd24 for therapy of rheumatoid arthritis | |
IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
MX2013006213A (es) | Proteina de funsion anticancer. | |
WO2012014214A3 (en) | Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension | |
PT2078038E (pt) | Agentes tensioativos reconstituídos apresentando propriedades melhoradas | |
NZ607615A (en) | Antibodies directed against il-17 | |
WO2010011952A3 (en) | Flip death effector domain derived peptides for inducing autophagy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FA | Abandonment or withdrawal |